# Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer

> **NCT01061359** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 1981 (actual)

## Conditions studied

- Breast Neoplasm

## Interventions

- **DRUG:** Epirubicin: Observational Study

## Key facts

- **NCT ID:** NCT01061359
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 1999-01
- **Primary completion:** 2009-10
- **Final completion:** 2009-10
- **Target enrollment:** 1981 (ACTUAL)
- **Last updated:** 2010-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061359

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061359, "Application Of Epirubicin Within A Neo-/Adjuvant Chemotherapy In Patients With Primary Breast Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01061359. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*